PARP1 inhibitors (PARPis) have been shown to selectively kill homologous recombination repair (HRR) deficient cancer cells1–3 by increasing PARP1-DNA binding due to suppression of autoPARylation of PARP1 on DNA4. This evidence concerns the gene PARP1 and cancer.